IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Lonza Breaks Ground on Singapore Biologics Plant

April 25, 2007 | Chemical Week Editorial Staff

Lonza and Bio*One Capital (Singapore) have broken ground on a previously announced project to build a large-scale commercial mammalian cell culture manufacturing facility in Singapore (CW, Dec. 13, 2006, p. 29). The plant is being built in the Tuas Biomedical Park, and will be Lonza’s second large-scale mammalian manufacturing plant in Singapore and its third worldwide. It will have up to four mammalian bioreactor trains, each with a flexible capacity of 1,000 liters-20,000 liters. Completion is scheduled by 2011. The investment could total $350 million...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa